Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IRAK4 | Q9NWZ3 | 14/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21765472 | 0.89 | IRAK4 (0.53) | IRAK4MAPTKDM4E | |
| SCHEMBL15714840 | 0.89 | IRAK4 (0.53) | IRAK4MAPTKDM4E | |
| SCHEMBL15688817 | 0.86 | IRAK4 (0.42) | IRAK4TGFBR1KDM4E | |
| SCHEMBL16873543 | 0.86 | IRAK4 (0.42) | IRAK4TGFBR1KDM4E | |
| SCHEMBL15688819 | 0.86 | IRAK4 (0.42) | IRAK4TGFBR1KDM4E | |
| SCHEMBL31160329 | 0.86 | LMNA (0.36) | IRAK4LMNAMAPK1TGFBR1HTT | |
| SCHEMBL20475993 | 0.85 | IRAK4 (0.41) | IRAK4LMNAMAPK1TGFBR1HTT | |
| SCHEMBL29751403 | 0.85 | IRAK4 (0.41) | IRAK4LMNAMAPK1TGFBR1HTT | |
| SCHEMBL31436589 | 0.84 | IRAK4 (0.45) | IRAK4 | |
| SCHEMBL31436637 | 0.84 | IRAK4 (0.45) | IRAK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250270190-A1 | KIT INHIBITORS | BLUEPRINT MEDICINES CORPORATION | 2025-08-28 | — | — | US | disclosed |
| CN-119585250-A | KIT inhibitors | 蓝图药品公司 | 2025-03-07 | — | — | CN | disclosed |
| EP-4511366-A1 | KIT INHIBITORS | Blueprint Medicines Corporation (US) | 2025-02-26 | — | — | EP | disclosed |
| WO-2023205226-A1 | KIT INHIBITORS | BLUEPRINT MEDICINES CORPORATION (US) | 2023-10-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250270190-A1 | KIT INHIBITORS | KIT, ABL1, APC | IRAK4 753/4885LMNA 3293/4885MAPK1 74/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.